Promegestone

Jump to navigation Jump to search
Promegestone
Promegestone.png
Clinical data
SynonymsR-5020; RU-5020
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H30O2
Molar mass326.472 g/mol
3D model (JSmol)

Promegestone (INN) (brand name Surgestone), also known as 17α,21-dimethyl-19-nor-Δ4,9-pregnadiene-3,20-dione, is a 19-norprogesterone derivative and steroidal progestin which was introduced in 1983 and is marketed in France, Portugal, and Argentina.[1][2][3][4] Indications include gynaecological conditions caused by luteal insufficiency, including premenopausal disorders, dysmenorrhea, and premenstrual syndrome.[4] Unlike some other progestins, promegestone is devoid of androgenic properties.[4]

In addition to its progestogenic properties, promegestone has also been found to act as a non-competitive antagonist of the nicotinic acetylcholine receptor.[5]


References

  1. R.A. Hill; H.L.J. Makin; D.N. Kirk (23 May 1991). Dictionary of Steroids. CRC Press. pp. 759–. ISBN 978-0-412-27060-4. Unknown parameter |coauthors= ignored (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  2. William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  3. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 883–. ISBN 978-3-88763-075-1.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  4. 4.0 4.1 4.2 Cain (11 September 1984). ANNUAL REPORTS IN MED CHEMISTRY V19 PPR. Academic Press. pp. 323–. ISBN 978-0-08-058363-1.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  5. Blanton MP, Xie Y, Dangott LJ, Cohen JB (February 1999). "The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface". Mol. Pharmacol. 55 (2): 269–78. PMID 9927618.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>